

Please type a plus (+) inside this box +

3-6-02

H
Box Science

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

10271-063

Total Pages

185

First Named Inventor or Application Identifier

Dingivan, Christine

Express Mail Label No.

EL 134 443 884 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. Applicant claims Small Entity status, see 37 C.F.R. § 1.27
3. Specification [Total Pages 183]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description of the Invention *(including drawings, if filed)*
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 USC 113) [Total Sheets]
5. Oath or Declaration [Total Sheets 2]
 - Newly executed (original or copy)
 - Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 19 completed)
 - i. DELETION OF INVENTORS(S)

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
6. Application Data Sheet. See 37 CFR 1.76

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)
11. English Translation Document *(if applicable)*
12. Information Disclosure Statement Copies of IDS
(IDS)/PTO-1449 Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(i).
Applicant must attach form PTO/SB/35 or it's equivalent
17. Other:

18. This application claims priority to U.S. provisional application Serial No. 60/273,098, filed March 2, 2001, U.S. provisional application 60/346,918, filed October 19, 2001, and U.S. provisional application Serial No. , filed February 19, 2002, each of which is incorporated herein by reference in its entirety.

19. CORRESPONDENCE ADDRESS

Customer Number:



20583

(Insert Customer No. or Attach bar code label here)

or Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PENNIE & EDMONDS LLP
 COUNSELLORS AT LAW
 1155 Avenue of Americas
 New York, N.Y. 10036-2711

ATTORNEY DOCKET NO. 10271-063Date: March 4, 2002

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant: Dingivan, Christine A.

Title of Invention: METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE
 DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER
 PROPHYLACTIC OR THERAPEUTIC AGENTS

PATENT APPLICATION FEE VALUE

| TYPE | NO. FILED | LESS | EXTRA | EXTRA RATE | FEE |
|---|-----------|------|-------|--------------|-------------|
| Total Claims | 138 | -20 | 118 | \$18.00 each | \$ 2,124.00 |
| Independent | 12 | -3 | 9 | \$84.00 each | \$ 756.00 |
| Minimum Fee | | | | | \$ 740.00 |
| Multiple Dependency Fee If Applicable (\$280.00) | | | | | \$ 280.00 |
| Total | | | | | \$ 3,900.00 |
| Applicant qualifies for the 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern | | | | | - \$ 0.00 |
| Total Filing Fee | | | | | \$ 3,900.00 |

- ☒ Priority of U.S. provisional application Serial No. 60/273,098, filed March 2, 2001, U.S. provisional application Serial No. 60/346,918, filed October 19, 2001, and Serial No. _____ to be assigned, filed February 19, 2002, is claimed under 35 U.S.C. § 119.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Anthony M. Insogna 35,203
 Anthony M. Insogna (Reg. No.)
 PENNIE & EDMONDS LLP

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

By: *Jennifer D. Chedec*
 Reg No. 46,617